ABBV Stock — Price, Charts & Analysis

AbbVie Inc. (ABBV) has a trailing P/E of 75.30x and a forward P/E of 16.37x. This places ABBV in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

ABBV trades with 75.30x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether ABBV looks overvalued or undervalued.

ABBV's P/E of 75.30x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

ABBV's trailing EPS is $3.48 and forward EPS is $16.24. Reported earnings growth is 290.40%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit AbbVie Inc. generated for each share. ABBV's trailing EPS is $3.48, and investors usually prefer EPS that is positive and growing over time.

AbbVie Inc. has a market cap of $469.70B, making ABBV a large-cap stock based on the current market value shown on Worldtickers.

ABBV's latest stock price on Worldtickers is $265.80. The latest move is $3.97 or 1.52%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

ABBV's quote includes a latest price of $265.80. The market open is $260.70. Previous close is $261.83. The intraday range is $260.10 to $266.83.

ABBV is up in the latest quote, with a move of $3.97 or 1.52%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

ABBV generated $64.39B in trailing revenue. Revenue growth is 10.20%, which helps show whether demand is expanding or slowing.

ABBV's revenue growth is 10.20%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, ABBV shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $6.27B.

Gross margin is 72.79%. Margins show how efficiently AbbVie Inc. turns revenue into profit.

AbbVie Inc. carries $70.88B and holds $6.57B in cash.

ABBV holds $6.57B on its balance sheet.

ABBV's book value per share is -$3.36.

Yes, AbbVie Inc. pays a dividend of $6.92 per share annually. The dividend yield is 264.00%. The payout ratio is 190.40%.

ABBV's dividend yield is 264.00%. Its payout ratio is 190.40%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for ABBV. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through AbbVie Inc.'s investor relations materials.

ABBV's five-year average dividend yield is 360.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 77.44% of ABBV shares. Insiders hold 0.11% of shares. Ownership mix helps investors understand how much of AbbVie Inc. is held by professional investors and company insiders.

ABBV has 1.77B shares outstanding. Float shares are 1.76B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for ABBV, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for ABBV is $16.24. Earnings growth is 290.40%. Revenue growth is 10.20%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

ABBV's trailing EPS is $3.48. Forward EPS is $16.24. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

ABBV is in the Healthcare sector. Its earnings multiple is 75.30x. Its latest displayed growth metric is 10.20%. Compare these figures with sector peers before deciding whether AbbVie Inc. is stronger or weaker than average.

ABBV trades at $265.80. The stock trades at 75.30x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of AbbVie Inc.'s fundamentals.

ABBV risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.28, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

ABBV should be compared with companies in Drug Manufacturers - General. Its earnings multiple is 75.30x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

AbbVie Inc. (ABBV) operates in Healthcare, specifically Drug Manufacturers - General. AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables,

ABBV trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

ABBV stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

AbbVie Inc.'s official website listed on Worldtickers is www.abbvie.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

AbbVie Inc. employs about 57K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

AbbVie Inc. is headquartered in North Chicago, IL, United States. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

ABBV is in the Healthcare sector and the Drug Manufacturers - General industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

ABBV has traded between $190.75 and $267.47 over the past 52 weeks. At $265.80, it is 0.62% below the high and 39.34% above the low. The 52-week range helps gauge long-term price momentum.

ABBV is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $247.25 and its 200-day moving average is $223.77.

ABBV's RSI is 64.96. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

ABBV's latest RSI reading is 64.96, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for ABBV is near $241.20. Key resistance is near $267.47. Breaks above resistance or below support can change the short-term technical setup.

ABBV's nearest reported support level is $241.20. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

ABBV's nearest reported resistance level is $267.47. A breakout above resistance can improve momentum, especially when volume confirms the move.

ABBV trades about 6.69M shares daily on average. The latest displayed volume is 2.34M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

ABBV's MACD is 1.32, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

ABBV is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 64.96 (neutral). MACD is bullish. Nearest support is around $241.20. Resistance is around $267.47. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $253.34 (4.92% from price). MA50 is $247.25 (7.50% from price). MA200 is $223.77 (18.78% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. ABBV's MA20 is $253.34. MA50 is $247.25. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

ABBV's pivot is near $262.75. Support is near $241.20. Resistance is near $267.47. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for ABBV is near $254.74. These levels help define risk and possible follow-through zones after a breakout or breakdown.

ABBV's Bollinger range is roughly $238.55 to $268.12. Band width is near 11.67%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

ABBV's ATR-based typical daily range is about 2.32%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 2.34M shares. Average volume is about 6.69M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

ABBV's all-time high shown on Worldtickers is $267.47. Its all-time low is $33.33. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

ABBV has a beta of 0.28, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.